Bloom M, Podder S, Dang H, Lin D
Int J Mol Sci. 2025; 26(5).
PMID: 40076561
PMC: 11900920.
DOI: 10.3390/ijms26051936.
Liu Y, Gong L, Feng J, Xiao C, Liu C, Chen B
J Nanobiotechnology. 2025; 23(1):194.
PMID: 40059141
PMC: 11892300.
DOI: 10.1186/s12951-025-03170-y.
Hua Q, Li Z, Weng Y, Wu Y, Zheng L
Front Med. 2025; .
PMID: 40048137
DOI: 10.1007/s11684-025-1124-8.
Hosui A, Hayata N, Kurahashi T, Namiki A, Okamoto A, Aochi K
Cancers (Basel). 2025; 17(2.
PMID: 39857967
PMC: 11763424.
DOI: 10.3390/cancers17020185.
Oura K, Morishita A, Tadokoro T, Fujita K, Tani J, Kobara H
Int J Mol Sci. 2025; 25(24.
PMID: 39769351
PMC: 11679663.
DOI: 10.3390/ijms252413590.
Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report.
Qin H, Yan H, Zhang X, Huang Z, Chen Y, Zhang Y
Front Oncol. 2024; 14:1390299.
PMID: 39723389
PMC: 11668696.
DOI: 10.3389/fonc.2024.1390299.
The Vascular Endothelial Growth Factor-A121/Vascular Endothelial Growth Factor-A165 Ratio as a Predictor of the Therapeutic Response to Immune Checkpoint Inhibitors in Gastric Cancer.
Hamada Y, Tanoue K, Arigami T, Yamakuchi M, Okawa M, Matsushita D
Cancers (Basel). 2024; 16(23).
PMID: 39682145
PMC: 11640175.
DOI: 10.3390/cancers16233958.
PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies.
Jin M, Fang J, Peng J, Wang X, Xing P, Jia K
Mol Cancer. 2024; 23(1):266.
PMID: 39614285
PMC: 11605969.
DOI: 10.1186/s12943-024-02176-8.
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer.
Sweis R, Chatta G, Jain R, Moon H, Delacroix S, Fang A
Clin Cancer Res. 2024; 31(2):299-307.
PMID: 39576210
PMC: 11747792.
DOI: 10.1158/1078-0432.CCR-24-1728.
Utility of atezolizumab plus bevacizumab, carboplatin, and paclitaxel combination for the treatment of advanced non-squamous non-small cell lung cancer patients with malignant pleural effusion.
Hisakane K, Atsumi K, Seike M, Hirose T
Transl Lung Cancer Res. 2024; 13(9):2106-2115.
PMID: 39430336
PMC: 11484719.
DOI: 10.21037/tlcr-24-347.
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.
Inocencio J, Mitrasinovic S, Asad M, Parney I, Zang X, Himes B
Front Immunol. 2024; 15:1424396.
PMID: 39346924
PMC: 11427296.
DOI: 10.3389/fimmu.2024.1424396.
Enhanced efficacy of combined VEGFR peptide-drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma.
Liu J, Bai Y, Liu X, Zhou B, Sun P, Wang Y
Sci Rep. 2024; 14(1):21728.
PMID: 39289512
PMC: 11408695.
DOI: 10.1038/s41598-024-72907-w.
The complexity of immune evasion mechanisms throughout the metastatic cascade.
Haynes N, Chadwick T, Parker B
Nat Immunol. 2024; 25(10):1793-1808.
PMID: 39285252
DOI: 10.1038/s41590-024-01960-4.
PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model.
Masuda C, Onishi S, Yorozu K, Kurasawa M, Morinaga M, Wakita D
Clin Exp Metastasis. 2024; 41(6):909-924.
PMID: 39231916
PMC: 11607052.
DOI: 10.1007/s10585-024-10309-y.
Targeting the tumour vasculature: from vessel destruction to promotion.
Guelfi S, Hodivala-Dilke K, Bergers G
Nat Rev Cancer. 2024; 24(10):655-675.
PMID: 39210063
DOI: 10.1038/s41568-024-00736-0.
Soluble FLT-1 in angiogenesis: pathophysiological roles and therapeutic implications.
Wazan L, Widhibrata A, Liu G
Angiogenesis. 2024; 27(4):641-661.
PMID: 39207600
DOI: 10.1007/s10456-024-09942-8.
Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/PD-L1 antibodies in extensive-stage small cell lung cancer: a....
Yang P, Luo H, Zhao L, Xiong F, Tang C
J Thorac Dis. 2024; 16(7):4391-4399.
PMID: 39144292
PMC: 11320278.
DOI: 10.21037/jtd-24-394.
From foes to friends: rethinking the role of lymph nodes in prostate cancer.
Gupta R, Das C, Nair S, Pedraza-Bermeo A, Zahalka A, Kyprianou N
Nat Rev Urol. 2024; 21(11):687-700.
PMID: 39095580
DOI: 10.1038/s41585-024-00912-9.
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy.
Chen J, Duan Y, Che J, Zhu J
Cancer Commun (Lond). 2024; 44(9):1047-1070.
PMID: 39051512
PMC: 11492303.
DOI: 10.1002/cac2.12596.
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K
Signal Transduct Target Ther. 2024; 9(1):176.
PMID: 39034318
PMC: 11275440.
DOI: 10.1038/s41392-024-01868-3.